NRX Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc. operates under ticker BRPA following its business combination with Big Rock Partners Acquisition Corp., a blank-check company that completed its IPO in 2018 targeting the healthcare sector. Sponsored by Big Rock Partners, the SPAC identified NRX Pharmaceuticals, a clinical-stage biopharmaceutical company focused on treatments for central nervous system disorders and severe COVID-19, as its merger target. The 10-Q filed on May 21, 2021, under accession number 0001193125-21-168067 reflects quarterly operations of the post-combination entity as NRX continued advancing its therapeutic pipeline. Institutional investors and researchers tracking healthcare SPAC transactions and post-merger performance can access complete filing histories, deal timelines, and company data for BRPA by signing up at SpacDesk.